Skip to main content

More on Hospital Price Transparency

The Centers for Medicare & Medicaid Services (CMS) recently issued an update on its hospital price transparency enforcement efforts. This update is part of the agency's larger goal to increase transparency and empower consumers to make informed healthcare decisions. Under the new rule, hospitals that fail to comply with the transparency requirements will face penalties of up to $300 per day, and the CMS will also publicly disclose the names of non-compliant hospitals. This move is a significant step towards holding hospitals accountable for providing accurate and easily accessible pricing information to their patients.


The CMS's update is a much-needed move towards transparency in the healthcare industry. It's no secret that medical bills are often complicated and difficult to understand, leaving many patients feeling helpless and vulnerable. By mandating that hospitals provide clear pricing information, patients will have the tools they need to make informed decisions about their healthcare. This will enable them to better plan and budget for medical procedures, avoiding the surprise bills that often come with hidden fees and unclear pricing.

However, it's important to note that the rule only applies to hospitals, and not other healthcare providers like doctors or clinics. To truly empower patients and increase transparency, these other providers should also be required to provide clear pricing information. Additionally, while the penalties for non-compliance are significant, it remains to be seen if they will be enough to incentivize hospitals to comply. The CMS will need to continue to monitor compliance closely and ensure that hospitals are following the guidelines.

CMS's update on hospital price transparency enforcement is a significant step towards empowering patients and increasing transparency in the healthcare industry. By holding hospitals accountable for providing clear pricing information, patients will be better equipped to make informed decisions about their healthcare. 


Comments

Popular posts from this blog

Innovative Models for Lowering Drug Spending

Recently, much has been written about the escalating costs of drug prices in the US. Increasing drug prices are present challenges to those who struggle with affordability and access to their medications. The Inflation Reduction Act brought changes to the way the Medicare program reimburses for prescription drugs. Last year, President Biden challenged the Center for Medicare and Medicaid Innovation (CMMI) to develop and test new payment models that can support value-based payments and promote high-quality healthcare. CMMI has recently proposed three models intended to improve affordability and access to drugs as well as measuring the feasibility of implementation.       1. The Medicare High-Value Drug List Model Under this model, Part D plans would be encouraged to offer a low, fixed co-payment across all cost-sharing phases of the Part D drug benefit for a standardized Medicare list of generic drugs that treat chronic conditions. Patients picking plans that participate in the Model wi

FDA Pilot Program for Certain In Vitro Diagnostic Tests

The U.S. Food and Drug Administration (FDA) has announced a pilot program designed to improve oncology patient care by establishing minimum performance standards for in vitro diagnostic tests (IVDTs) used with a limited number of oncology drug products. An IVDT is a device that provides critical information for the safe and effective use of a therapeutic product. The FDA typically requires a companion diagnostic to receive marketing authorization concurrently with the approval of the corresponding therapeutic product. However, in cases where no satisfactory alternative treatment exists for a serious or life-threatening condition, the FDA may approve a therapeutic product even without a companion IVDT. Currently, laboratory developed tests (LDTs) are being used in such cases, and the FDA exercises enforcement discretion regarding these tests. The pilot program aims to improve drug selection and patient care by establishing minimum performance characteristics for certain LDTs used in id

Bridging the Gap: The Long Road from FDA Approval to Medicare Coverage

A new study published in JAMA Health Forum reveals that the road to Medicare coverage for novel medical technologies is a long and winding one. Researchers found that only 44% of innovative devices and diagnostics approved by the FDA from 2016-2019 had even “nominal” Medicare coverage by 2022. This data highlights major hurdles in the system that delay patient access to beneficial emerging technologies. About the Research The study examined 281 novel products cleared through the FDA from 2016-2019 via the high-risk premarket approval, de novo, and breakthrough 510(k) pathways. These included things like groundbreaking diagnostic tests, implantable devices, and other innovative treatment technologies. The goal was to measure how long it took to establish national or regional Medicare coverage policies for these newly approved products. This is important because Medicare coverage is required before hospitals, physicians and patients can reliably access new technologies. Key Findings The